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Abstract 
Background: Despite the high rate of virological success of combined antiretroviral therapy (cART), 
HIV infected individuals continue to fail. In this contest, it is unclear whether having previously 
experienced virological failure (VF) of cART remains an important predictor of future risk of VF in 
people receiving cART in modern times. We investigated the rate of VF and factors potentially 
associated with this event in 9,220 HIV-1 infected patients enrolled in the Icona Cohort who 
showed a stable viral suppression on modern cART regimens after January 1, 2006. 
Methods:  We investigated two main exposure factors: current calendar period (2006-2009; 2010-
2013; 2014-2017) and number of VFs (0; 1-3; >3) prior to baseline. Relative rates of VF were 
estimated from fitting a Poisson regression model. 
Results: Seven-hundred-seventy-nine patients experienced VF over follow-up for an overall rate of 
2.08 per 100 person years of follow-up (PYFU, 95%CI: 1.93-2.22). The rate of VF increased with 
higher numbers of previous VFs: patients with >3 previous VFs had a rate of 4.87 (4.10-5.78), 2.75-
fold higher than that observed in patients without any previous VF (p<0.001). The rate of VF was 
lower in recent years: 3.81 (3.36, 4.32) in 2006-2009; 1.36 (1.20-1.53) in 2014-2017 (p<0.001). 
Other factors independently associated with lower risk of VF were Italian origin, longer history of 
virological suppression, and university education level.  
Conclusions: In HIV-infected patients virologically suppressed after January 2006, the rate of VF 
continues to show a decline even in the most recent years. Previous VFs should be carefully 
considered. 
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1. Background 
Despite huge advances in terms of the impact of combined antiretroviral therapy (cART) on HIV-
related morbidity and mortality, patients continue to fail therapy [1-4]. A history of prior 
virological failure (VF) has been shown to be associated with the risk of subsequent VF, emergence 
of resistance, and death [5-7]. However, the dynamics of VF in HIV-infected population receiving 
modern cART and factors associated with a greater risk of VF in this population have been not 
thoroughly investigated [8,9]. Specifically, in people whose viral load is currently suppressed, it is 
unclear whether having previously experienced VF of cART remains an important predictor of 
future risk of VF in people receiving cART in modern times. There are several factors that could 
lead to the development of VF, such as lack of adherence, which can impact on the efficacy of 
different drug regimens [10,11], high levels of pre-cART viremia, which are associated with a lower 
probability of achieving virological suppression, and drug resistance [12-18].  
In the present work, we aimed at identifying the rate and the presence of independent predictors 
of VF in HIV-1 infected individuals with plasma viral load ≤50 copies/mL on modern cART regimens 
after January 1, 2006.  
2. Study design 
2.1. Study population 
All patients analyzed were from the ICONA Foundation Study (ICONA), a multi-centre prospective 
observational study (http://www.fondazioneicona.org/).  Each patient included in the present 
analysis had a record of two consecutive plasma HIV-RNA ≤50 copies/mL after January 1, 2006: 
baseline was defined at the date of the second of these values.  A patient was classified as having 
experienced VF to a regimen before baseline if, after at least 4 months from starting the regimen 
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and while he/she was receiving the same regimen, plasma HIV-RNA was still >400 copies/mL. A 
counter for the number of regimens to which a participant had experienced VF prior to baseline 
was constructed. Plasma HIV-RNA cut-off was chosen by considering the different limits of 
quantification of assays used to quantify this parameter before 2006.  
2.1. Estimation of rates of virological failure during prospective follow-up by Poisson regression 
model 
VF over prospective follow-up was defined at the time of the first of two consecutive values of 
HIV-RNA >50 copies/mL while the person was still receiving cART after baseline. Participants’ 
follow-up accrued from baseline until the date of estimated VF or the date of their last available 
HIV-RNA value. Rates of current VF were calculated as number of VF divided by person years of 
follow-up (PYFU) and unadjusted and adjusted relative rates (RR) were estimated from fitting a 
Poisson regression model. Main exposure factors investigated were: i) current calendar year 
periods of baseline (stratified as: 2006-2009, 2010-2013, 2014-2017); ii) number of VFs 
experienced before baseline (stratified as: 0, 1-3, >3). Whether the risk associated with previous 
number of VFs varied according to current calendar period of viral suppression was formally 
investigated by fitting an interaction term in the Poisson regression model. The association 
between other socio-demographic, viro-immunological and clinical factors measured at baseline 
and the risk of VF were also investigated. Analyses were repeated after using a plasma HIV-RNA 
value of 200 copies/mL as the threshold to define VF.  
All the analyses were performed using SAS version 9.4 (SAS Institute Cary NC, U). In all the 
analyses a p-value <0.05 was considered as statistically significant. 
3. Results 
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3.1. Patients’ characteristics  
Nine-thousand and two-hundred-twenty HIV-infected patients, who had been under viral 
suppression after January 1, 2006 were included. The median (interquartile range, IQR) calendar 
year of baseline was 2012 (2009, 2015). At baseline, patients have been virologically suppressed 
for a median (IQR) of 20 (9, 36) months and have been subsequently followed for a total of 37,499 
PYFU. Baseline characteristics, stratified by calendar year periods at baseline, and previous history 
of VFs are shown in Table 1, Table 2 and Figure 1. 
  
3.2. Rates of virological failures during follow-up and independent predictors  
Seven-hundred and seventy-nine patients showed a current VF (cut-off 50 copies/mL) with a rate 
of 2.08 per 100 PYFU (95%CI: 1.93-2.22). The median value of HIV-RNA (log10) at VF did not differ 
among the 3 current time periods: 4.10 (2.99-4.88) in 2006-2009, 3.82 (2.95-4.72) in 2010-2013, 
3.91 (2.91-4.22) in 2014-2017 (p=0.320). In contrast, the risk of the current VF was higher with 
larger number of VFs experienced before baseline. Specifically, patients with >3 previous VFs had a 
rate (95%CI) of 4.87 (4.10-5.78) per 100 PYFU, 2.87-fold higher than that observed in patients 
without any previous VF (Table 3). This result was confirmed after controlling for potential 
confounding factors (adjusted RR=2.75; 95% CI: 2.13-3.56, p<0.001). 
In addition, the rate of VF was lower with more recent calendar years, ranging from 3.81 (3.36, 
4.32) in 2006-2009 to 1.36 (1.20-1.53) in 2014-2017. This association remained significant after 
adjustment for a number of potential confounding factors: adjusted RR=0.36 (95%CI: 0.29-0.44, 
p<0.001: comparison 2014-2017 vs. 2006-2009). The association between number of previous 
failures and the risk of subsequent VF was also confirmed in different multivariable models after 
controlling for several socio-demographic, viro-immunological and clinical variables 
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(Supplementary Table 1), and did not vary by current calendar period. This was documented by 
the lack of evidence for an interaction between previous VFs and calendar years (p=0.18, 
Supplementary Figure 1). 
Other independent predictors negatively associated with the risk of VF were Italian origins, a 
longer duration of time with virological suppression, declaring University as the highest level of 
education achieved, and use of efavirenz (Table 3). The GSS at baseline showed no association 
with the risk of VF. 
We obtained similar results after repeating the analyses with a plasma HIV-RNA value of 200 
copies/mL as the threshold to define VF (Supplementary Table 2). 
4. Discussion 
In our large cohort of virologically suppressed HIV-1 infected patients, we found that, after 
controlling for a number of demographic, health-related, viro-immunologic and therapeutic 
factors, the rate of VF continues to show a decline even in the most recent study period, i.e. 2014-
2017. Although the association between history of previous VFs on cART and subsequent risk of VF 
has been previously documented [5-7], our data extend this finding to more recent years for 
people exposed to modern cART. In addition, our data show that, despite the introduction of new 
drugs/drug classes with reduced cross-resistance and the increased tolerability of modern 
compounds, the impact of having virologically failed in the past remains unchanged on the current 
risk of VF.   
Other factors were identified as independent predictors of higher risk of VF over prospective 
follow-up and should be considered to identify people at greater risk of treatment failure: foreign 
nationality, shorter duration of viral suppression, and having the highest level of education lower 
than University.  We understand that our large cohort study is observational, so that issues such a 
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confounding and collision are less likely to be adequately controlled as it is in randomized trial. On 
the other hand, not many trials have sample sizes or duration of follow-up similar to that of our 
study, which extends over several decades and has allowed the time-periods comparison. 
 In conclusion, our data supports the concept that people with a current suppressed plasma viral 
load but a history of extensive VF (>3 regimens) are still a fragile population for whom careful 
monitoring of viral load should be maintained. Similarly, even in our ART modern era, a history of 
virological failure should be carefully examined and accounted for when a treatment switch is 
needed. 
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Figure legends 
Figure 1. Antivirals included in the suppressive regimen received at baseline among the overall 
patients analyzed in study (panel A), according to calendar year (panel B) and to previous 
virological failures (panel C). Among the antiretrovirals used at baseline, tenofovir was the 
nucleoside reverse transcriptase inhibitor (NRTI) mostly used (71.8%) together with emtricitabine 
(66.4%) or lamivudine (3.7%). As far as the third drug used in the current regimen, 3,494 (37.9%) 
patients were receiving a non-NRTI (NNRTI), 3,745 (40.6%) were treated with a ritonavir-boosted 
protease inhibitor, while 1,941 (21.0%) were treated with an integrase inhibitor.   
Supplementary figure 1. Rates of VF >50 copies/mL according to current calendar period (3 time 
periods examined) and number of VF >400 copies/mL experienced before baseline. PYFU: person 
years of follow-up. 
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